ADMA Biologics Inc $ADMA Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC raised its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 33.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 356,151 shares of the biotechnology company’s stock after buying an additional 90,223 shares during the quarter. Rafferty Asset Management LLC’s holdings in ADMA Biologics were worth $5,221,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. American Century Companies Inc. increased its stake in ADMA Biologics by 1.8% in the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after purchasing an additional 84,934 shares in the last quarter. Westfield Capital Management Co. LP purchased a new stake in ADMA Biologics during the third quarter worth $74,866,000. Roberts Glore & Co. Inc. IL acquired a new stake in ADMA Biologics in the third quarter valued at $377,000. AXQ Capital LP purchased a new position in shares of ADMA Biologics in the third quarter valued at $289,000. Finally, Clearstead Advisors LLC raised its stake in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ADMA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and an average target price of $28.50.

ADMA Biologics Stock Up 6.5%

ADMA opened at $16.58 on Tuesday. The firm has a market cap of $3.95 billion, a P/E ratio of 27.63 and a beta of 0.51. The business’s fifty day simple moving average is $17.19 and its 200 day simple moving average is $16.80. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same quarter in the previous year, the company posted $0.46 EPS. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. As a group, equities research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.